Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221726 | 0.92 | PRMT6 (0.35) | PRMT6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL17445620 | 0.88 | CCNB2 (0.39) | PRMT6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL17445621 | 0.82 | CCNB2 (0.31) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL19221723 | 0.80 | CCNB2 (0.32) | CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL19221725 | 0.80 | CCNB2 (0.38) | PRMT6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL30504224 | 0.75 | PRMT6 (0.37) | PRMT6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL13443481 | 0.74 | TDP1 (0.41) | PRMT6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL16039265 | 0.74 | P2RY1 (0.39) | PRMT6ADORA1ADORA3ADORA2A | |
| SCHEMBL20052009 | 0.74 | CCNB2 (0.44) | PRMT6CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20052944 | 0.73 | AHCY (0.43) | PRMT6CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | PRMT6 2789/4885CCNB2 3230/4885CDK1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.